The Post-Marketing Surveillance of Human Papilloma Virus Vaccine

Abstract

Abstract: Objective To provide information for the post-marketing surveillance ofhuman papilloma virus (HPV) vaccine in China. Methods The data of HPV vaccine of post-market surveillance from other countries, especially of passive surveillance system, and the hotspots of safety issues were summarized in the paper. Results and Conclusion HPV vaccine is one of the most import methods to againstcervical cancer and has been introduced in the national immunization programme of many countries. Based on the surveillance data, the most common adverse events following vaccination are slight and unserious. However the causality association between HPV vaccine and autoimmune diseases and primary ovarian failure should be evaluated based on more studies.

Key words: human papilloma virus vaccine, post-marketing surveillance, autoimmune diseases, primary ovarian failure

CLC Number:

R994.11

WANG Ya-li. The Post-Marketing Surveillance of Human Papilloma Virus Vaccine[J]. Chinese Journal of Pharmacovigilance, 2017, 14(7): 439-442.

References

[1] Stillo M, Carrillo Santisteve P, Lopalco P L. Safety of human papillomavirus vaccines: a review[J]. Expert Opin Drug Saf,2015,14(5):697-712.
[2] WHO.Guide to introducing HPV vaccine into national immunization programmes[EB/OL].(2016-12) [2017-03-10].http://www.who.int/immunization/documents/ISBN_9789241549769/en/.
[3] WHO.Comprehensive cervical cancer control A guide to essential practice[EB/OL].(2014-12) [2017-03-10].http://www.who.int/reproductivehealth/publications/cancers/cervicalcancerguide/en/.
[4] Gee J, Weinbaum C, Sukumaran L, et al.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States[J]. Hum Vaccin Immunother.2016, 12( 6) :1406-1417.
[5] CFDA.对十二届全国人大四次会议第3403号建议的答复（关于加快HPV疫苗内地上市进程的建议）[EB/OL]. (2016-9-12)[2017-03-10].http://www.sda.gov.cn/WS01/CL1744/166873.html.
[6] Angelo M G, Zima J, Tavares Da Silva F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4years of experience[J].Pharmacoepidemiol Drug Saf,2014,23(5):456-465.
[7] Vichnin M, Bonanni P, Klein N P, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015[J].Pediatr Infect Dis J, 2015,34(9):983-991.
[8] World Health Organization. Global Advisory Committee on Vaccine Safety, 11-12 December 2013[J].Wkly Epidemiol Rec,2014,89(7):53-60.
[9] Angelo M G, David M P, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme[J].Pharmacoepidemiol Drug Saf,2014,23(5):466-479.
[10] Coelho P L, da Silva Calestini G L, Alvo F S, et al. Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis[J]. Rev Paul Pediatr,2015,33(4):474-482.
[11] 张倩婷,王亚丽,曲毅.我国疫苗上市后主动监测模式的探讨[J].中国药物警戒.2016,13(11):673-675.
[12] Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States[J]. MMWR Morb Mortal Wkly Rep,2014,63(29):620-624.
[13] Markowitz L E, Dunne E F, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep,2014,63(5):1-30.
[14] Slade B A, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine[J]. JAMA,2009,302(7):750-757.
[15] Harris T, Williams D M, Fediurek J, et al. Adverse events following immunization in Ontario's female school-based HPV program[J]. Vaccine,2014,32(9):1061-1066.
[16] ubelj M, U akar V, Kraigher A, et al. Adverse events following school-based vaccination of girls with quadrivalent human papillo-mavirus vaccine in Slovenia, 2009 to 2013[J]. Euro Surveill,2016,21(14)：1-6.
[17] Gee J, Naleway A, Shui I, et al.Monitoring the safety of quadrivalenthuman papillomavirus vaccine: findingsfrom the Vaccine Safety Datalink[J].Vaccine,2011,29(46):8279-8284.
[18] Shoenfeld Y, Agmon-Levin N. 'ASIA': autoimmune/inflammatory syndrome induced by adjuvants[J]. J Autoimmun,2011,36(1):4-8.
[19] Forinash A B, Yancey A M, Pitlick J M, et al. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy[J].Ann Pharmacother,2011,45(2):258-262.
[20] Lehtinen M, Eriksson T, Apter D, et al. Safety of the human papill-omavirus(HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial[J]. Hum Vaccin Immunother,2016,12(12):3177-3185.
[21] Chao C, Klein N P, Velicer C M, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine[J]. J Intern Med,2012,271(2):193-203.
[22] Geier D A, Geier M R. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events[J].ClinRheumatol,2015,34(7):1225-1231.
[23] Komorowska B. Autoimmune premature ovarian failure[J].Menopause Rev,2016,15(4): 210-214.
[24] Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis[J].Curr Opin Obstet Gynecol,2015,27(4):265-270.
[25] Colafrancesco S, Perricone C, Tomljenovic L, et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants[J].Am J Reprod Immunol,2013,70(4):309-316.
[26] Little D T, Ward H R. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice[J]. J Investig Med High Impact Case Rep,2014,2(4)：1-11.
[27] Little D T, Ward H R. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papilloma virus vaccination[EB/OL].(2012-09-30)[2017-03-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543769/pdf/bcr-2012-006879.pdf.
[28] Hawkes D, Buttery J P. Human papillomavirus vaccination and primary ovarian insufficiency: an association based on ideology rather than evidence[J].Curr Opin Obstet Gynecol,2016,28(1):70-72.